Multigene DNA prime-boost vaccines for SHIV89.6P

被引:15
作者
Doria-Rose, NA
Pierce, CC
Hensel, MT
Sutton, WF
Sheikh, N
Polacino, P
Kuller, L
Zhu, YD
Hu, SL
Anderson, D
Haigwood, NL
机构
[1] Seattle Biomed Res Inst, Seattle, WA 98109 USA
[2] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA
[3] Washington Natl Primate Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
[5] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
关键词
dose; Gene Gun; prime-boost; SHIV89.6P; vaccine;
D O I
10.1034/j.1600-0684.2003.00028.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
We assessed four prime-boost vaccine regimens with a Gene Gun component for SHJV89.6P in Macaca nemestrina. A dosing, experiment using beta-galactosidase plasmid showed that 30 or 45 shots per dose elicited higher titer antibody than smaller doses. For SHIV89.6P, we administered a six-plasmid vaccine capable of producing non-infectious virions in vivo in combination with either vaccinia recombinants or inactivated virus. DNA prime/vaccinia boost, or the reverse, elicited strong immune responses. The SHIV89.6P challenge virus was grown in M. nemestrina peripheral blood mononuclear cells and titered in vivo intrarectally. As has been observed for SHIV89.6P in M. mulatta, the infected M. nemestrina experienced rapid and severe loss of circulating CD4(+) T cells. Vaccinated macaques were challenged three weeks after the last boost. DNA prime/vaccina boost or vaccina prime/DNA boost protected 11/12 animals from acute CD4(+) T cell depletion and disease, while other regimens were not effective.
引用
收藏
页码:218 / 228
页数:11
相关论文
共 35 条
[1]   The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals [J].
Addo, MM ;
Altfeld, M ;
Rosenberg, ES ;
Eldridge, RL ;
Philips, MN ;
Habeeb, K ;
Khatri, A ;
Brander, C ;
Robbins, GK ;
Mazzara, GP ;
Goulder, PJR ;
Walker, BD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1781-1786
[2]   Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine [J].
Amara, RR ;
Smith, JM ;
Staprans, SI ;
Montefiori, DC ;
Villinger, F ;
Altman, JD ;
O'Neil, SP ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McNicholl, JM ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (12) :6138-6146
[3]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[4]   Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys [J].
Barouch, DH ;
Craiu, A ;
Kuroda, MJ ;
Schmitz, JE ;
Zheng, XX ;
Santra, S ;
Frost, JD ;
Krivulka, GR ;
Lifton, MA ;
Crabbs, CL ;
Heidecker, G ;
Perry, HC ;
Davies, ME ;
Xie, H ;
Nickerson, CE ;
Steenbeke, TD ;
Lord, CI ;
Montefiori, DC ;
Strom, TB ;
Shiver, JW ;
Lewis, MG ;
Letvin, NL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) :4192-4197
[5]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[6]   Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection [J].
Betts, MR ;
Ambrozak, DR ;
Douek, DC ;
Bonhoeffer, S ;
Brenchley, JM ;
Casazza, JP ;
Koup, RA ;
Picker, LJ .
JOURNAL OF VIROLOGY, 2001, 75 (24) :11983-11991
[7]   Compact, synthetic, vaccinia virus early/late promoter for protein expression [J].
Chakrabarti, S ;
Sisler, JR ;
Moss, B .
BIOTECHNIQUES, 1997, 23 (06) :1094-1097
[8]   SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN [J].
COONEY, EL ;
COLLIER, AC ;
GREENBERG, PD ;
COOMBS, RW ;
ZARLING, J ;
ARDITTI, DE ;
HOFFMAN, MC ;
HU, SL ;
COREY, L .
LANCET, 1991, 337 (8741) :567-572
[9]   Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection [J].
Egan, MA ;
Charini, WA ;
Kuroda, MJ ;
Schmitz, JE ;
Racz, P ;
Tenner-Racz, K ;
Manson, K ;
Wyand, M ;
Lifton, MA ;
Nickerson, CE ;
Fu, TM ;
Shiver, JW ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2000, 74 (16) :7485-7495
[10]   Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV [J].
Fuller, DH ;
Simpson, L ;
Cole, KS ;
Clements, JE ;
Panicali, DL ;
Montelaro, RC ;
MurpheyCorb, M ;
Haynes, JR .
IMMUNOLOGY AND CELL BIOLOGY, 1997, 75 (04) :389-396